Blood cancers

Early intervention with daratumumab may head off myeloma

Daratumumab monotherapy may be useful in patients with intermediate-risk or high-risk smouldering multiple myeloma (SMM) to delay their progression to MM. A phase 2 study of the monoclonal antibody in 123 patients from 47 sites worldwide said a primary end point of progressive disease (PD)/death rate less 0.346/ patient-year suggested activity against SMM. It found ...

Already a member?

Login to keep reading.

© 2021 the limbic